We hypothesize that targeting p130Cas, PKN3, and their co‐operation may be exploited in cancer therapy and, based on our insight in PKN3 signaling in osteoclasts, potentially in pathophysiological signaling related to bone disease such as osteoporosis, rheumatoid arthritis, and periodontal disease as well. Here, PKN3 is linked to periodontal disorder.